Modulation of immunoglobulin dysregulation in graft versus host-and systemic lupus erythematosus-like diseases by malononitrilamidesSCHORLEMMER, H. U; BARTLETT, R. R.Transplantation proceedings. 1998, Vol 30, Num 8, pp 4153-4155, issn 0041-1345Conference Paper

Long-term allograft survival and tolerance induction by the synergistic activity of malononitrilamides and tacrolimusSCHORLEMMER, H. U; BARTLETT, R. R; LINDNER, J. K et al.Transplantation proceedings. 1998, Vol 30, Num 8, pp 4099-4103, issn 0041-1345Conference Paper

Leflunomide prevents the development of experimentally induced myasthenia gravisVIDIC-DANKOVIC, B; KOSEC, D; DAMJANOVIC, M et al.International journal of immunopharmacology. 1995, Vol 17, Num 4, pp 273-281, issn 0192-0561Article

Effects of leflunomide on immune responses and models of inflammationBARTLETT, R. R; ANAGNOSTOPULOS, H; ZIELINSKI, T et al.Springer seminars in immunopathology. 1993, Vol 14, Num 4, pp 381-394, issn 0344-4325Article

Synthesis of basic substituted pyridines: a new class of antiasthmatic-antiallergic agentsANAGNOSTOPOULOS, H; BARTLETT, R. R; ELBEN, U et al.European journal of medicinal chemistry. 1989, Vol 24, Num 3, pp 227-232, issn 0223-5234Article

Inhibition of murine IgE and immediate cutaneous hypersensitivity responses to ovalbumin by the immunomodulatory agent leflunomideJARMAN, E. R; KUBA, A; MONTERMANN, E et al.Clinical and experimental immunology (Print). 1999, Vol 115, Num 2, pp 221-228, issn 0009-9104Article

The new immunosuppressants, the malononitrilamides MNA 279 and MNA 715, inhibit various graft-vs.-host diseases (GvHD) in rodentsSCHORLEMMER, H. U; KURRLE, R; BARTLETT, R. R et al.Drugs under experimental and clinical research. 1997, Vol 23, Num 5-6, pp 167-173, issn 0378-6501Article

Malononitrilamides inhibit the development of various murine graft-vs-host diseasesSCHORLEMMER, H. U; KURRLE, R; BARTLETT, R. R et al.Transplantation proceedings. 1996, Vol 28, Num 6, pp 3043-3047, issn 0041-1345Conference Paper

Leflunomide therapy following penetrating keratoplasty in the ratCOUPLAND, S. E; KLEBE, S; KAROW, A.-C et al.Graefe's archive for clinical and experimental ophthalmology. 1994, Vol 232, Num 10, pp 622-627, issn 0721-832XArticle

Immunomodulation of proteoglycan-induced progressive polyarthritis by leflunomideGLANT, T. T; MIKECZ, K; BARTLETT, R. R et al.Immunopharmacology (New York). 1992, Vol 23, Num 2, pp 105-116, issn 0162-3109Article

Analogues of leflunomide's primary metabolite, the malononitrilamides, prevent the development of graft-versus-host diseaseSCHORLEMMER, H. U; BARTLETT, R. R; KURRLE, R et al.Transplantation proceedings. 1997, Vol 29, Num 1-2, pp 1298-1301, issn 0041-1345Conference Paper

Effects of leflunomide (HWA 486) on expression of lymphocyte activation markersZIELINSKI, T; MÜLLER, H.-J; BARTLETT, R. R et al.Collection sécurité. 1993, Vol 38, pp C80-C82, issn 0538-4818, NSConference Paper

Immunosuppressive activity of 15-deoxyspergualin (15-DOS) on various models of rheumatoid arthritisSCHORLEMMER, H. U; BARTLETT, R. R; SCHLEYERBACH, R et al.Drugs under experimental and clinical research. 1991, Vol 17, Num 10-11, pp 471-484, issn 0378-6501Article

Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejectionBARTLETT, R. R; DIMITRIJEVIC, M; FINNEGAN, A et al.Agents and actions. 1991, Vol 32, Num 1-2, pp 10-21, issn 0065-4299, 12 p.Conference Paper

Cefodizime, an aminothiazolyl cephalosporin. IV: Influence on the immune systemLIMBERT, M; BARTLETT, R. R; DICKNEITE, G et al.Journal of antibiotics (Tokyo. 1968). 1984, Vol 37, Num 12, pp 1719-1726, issn 0021-8820Article

Malononitrilamides prevent the generation of oxygen radicals in mononuclear phagocytes and graft rejection in a rat modelSCHORLEMMER, H. U; BARTLETT, R. R; KURRLE, R et al.Transplantation proceedings. 1999, Vol 31, Num 1-2, pp 851-853, issn 0041-1345Conference Paper

Coadministration of malononitrilamides and tacrolimus induces tolerance in a rat skin allograft modelSCHORLEMMER, H. U; BARTLETT, R. R; LINDNER, J. K et al.Transplantation proceedings. 1999, Vol 31, Num 1-2, pp 1184-1188, issn 0041-1345Conference Paper

Immunomodulatory activity of malononitrilamides, derivatives of leflunomide's primary metabolite, on models of experimental rheumatoid arthritisSCHORLEMMER, H. U; BARTLETT, R. R; SCHLEYERBACH, R et al.Transplantation proceedings. 1998, Vol 30, Num 8, pp 4137-4139, issn 0041-1345Conference Paper

Inhibition of alloreactivity in the popliteal lymph node assay by malononitrilamidesSCHORLEMMER, H. U; BARTLETT, R. R; KURRLE, R et al.Transplantation proceedings. 1998, Vol 30, Num 4, pp 968-970, issn 0041-1345Conference Paper

Leflunomide, an immunorestoring drug for the therapy of autoimmune disorders, especially rheumatoid arthritisBARTLETT, R. R; BRENDEL, S; ZIELINSKI, T et al.Transplantation proceedings. 1996, Vol 28, Num 6, pp 3074-3078, issn 0041-1345Conference Paper

Modulation of effects of lipopolysaccharide on macrophages by a major outer membrane protein of Proteus mirabilis as measured in a chemiluminescence assayWEBER, G; HECK, D; BARTLETT, R. R et al.Infection and immunity. 1992, Vol 60, Num 3, pp 1069-1075, issn 0019-9567Article

Pharmacological profile of A85 4777, a novel antiiflammatory agent with nonclassical immunosuppressive propertiesBARTLETT, R. R; SCHLEYERBACH, R; SCHORLEMMER, K.-U et al.Transplantation proceedings. 1990, Vol 22, Num 4, pp 1666-1670, issn 0041-1345, 5 p.Conference Paper

Immunosuppressive therapy of experimental autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus by 15-deoxyspergualinSCHORLEMMER, H. U; BARTLETT, R. R; SCHLEYERBACH, R et al.International journal of immunotherapy. 1989, Vol 5, Num 1, pp 9-20, issn 0255-9625Article